Last reviewed · How we verify
Tinzaparin, High dose prophylactic anticoagulation
At a glance
| Generic name | Tinzaparin, High dose prophylactic anticoagulation |
|---|---|
| Also known as | HD-PA |
| Sponsor | Assistance Publique - Hôpitaux de Paris |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Intravenous Immunoglobulin for the Treatment of Acute Exacerbations of Idiopathic Pulmonary Fibrosis (PHASE3)
- Hamburg Edoxaban for Anticoagulation in COVID-19 Study (PHASE3)
- Rivaroxaban vs. Warfarin in CVT Treatment (PHASE3)
- Standard vs High Prophylactic Doses or Anticoagulation in Patients With High Risk of Thrombosis Admitted With COVID-19 Pneumonia (PROTHROMCOVID) (NA)
- ANTIcoagulation in Severe COVID-19 Patients (PHASE2)
- Thromboprophylaxis for Patients in ICU With COVID-19
- Full Dose Heparin Vs. Prophylactic Or Intermediate Dose Heparin in High Risk COVID-19 Patients (PHASE3)
- Preventing COVID-19 Complications With Low- and High-dose Anticoagulation (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: